The CPDR Biomarker Reference Laboratory will share unique resources, such as a minority enriched cohort, for verification and validation of panel/s of Early Detection Research Network developed biomarkers that are fitted to improve early detection among African Americans, Hispanics and Asians; continue to develop monoclonal antibodies and clinical grade assays to detect oncogenic rearrangements of ETS family members, and other frequently mutated or overexpressed gene products in prostate cancer (SPOP, CHAD1, AR, etc.); support pre-validation and validation studies of promising EDRN developed biomarkers; support longitudinal testing of validated biomarkers to improve the panel?s specificity in detection of aggressive prostate cancers; and to support centralized pathological examination of specimens for EDRN related pre-validation and validation studies to better determine, which biomarkers could be used to predict significant progression from Gleason score 6 cancers to 7+ cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
NIH Inter-Agency Agreements (Y01)
Project #
ACN17005001-1-0-1
Application #
10171361
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2020
Total Cost
Indirect Cost
Name
National Cancer Institute
Department
Type
DUNS #
City
State
Country
Zip Code